Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Update: India Approves Multiple New Vaccines

Plus, Wins And Losses For China Drug Developers

Executive Summary

India has issued emergency approvals for a number of new vaccines and extended eligible age groups for others, while developers of potential drug therapies in China see both gains and setbacks. 

You may also be interested in...



Biocon Joins Fray For Denosumab, Ustekinumab Biosimilars

Biocon is progressing trials for biosimilar rivals to Amgen’s Prolia/Xgeva (denosumab) and J&J’s Stelara (ustekinumab), even as it gears for other large opportunities coming its way via the Viatris deal including for blockbusters Humira and Eylea.

Biocon Joins Fray For Denosumab, Ustekinumab Biosimilars

Biocon is progressing trials for biosimilar rivals to Amgen’s Prolia/Xgeva (denosumab) and J&J’s Stelara (ustekinumab), even as it gears for other large opportunities coming its way via the Viatris deal including for blockbusters Humira and Eylea.

Biological E's COVID-19 Vaccine Launched, MD Says India Supplies To WHO Not Under Threat

Despite Indian companies not being able to honor COVID-19 vaccine export commitments, Biological E’s MD believes mitigating circumstances mean relations with the agency won’t be damaged. Meanwhile, Corbevax is being used in India's immunization program and a tech transfer for Johnson & Johnson’s COVID-19 vaccine is going ahead.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145635

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel